

Table S3. The association between nuclear SMAD4 expression and clinicopathological parameters in three subtypes of RCC

		Expression of SMAD4		
		Nuclear <i>H-Score</i> (N %)		* <i>P</i> <i>value</i>
Patient and tumor characteristics	Total No.Cases 209(N %)	Low (≤200)	High (200<)	
Age (y)				0.046
≤55.0	102(48.8)	93(44.5)	9(4.3)	
>55.0	107(51.2)	87(41.6)	20(9.6)	
Sex				0.671
Male	180(67.5)	120(57.4)	60(28.7)	
Female	29(32.5)	21(10.0)	8(3.8)	
RCC subtypes				0.034
ccRCC	158(75.6)	132(63.2)	26(12.4)	
ChRCC	17(8.1)	17(8.1)	0(0.0)	
pRCC	34(16.3)	31(14.8)	3(1.4)	
Tumor size(cm)				0.155
<4	43(20.6)	33(15.8)	10(4.8)	
4-7	72(34.4)	65(31.3)	7(3.3)	
7-10	50(23.9)	42(20.1)	8(3.8)	
>10	44(21.1)	40(19.1)	4(1.9)	
Tumor Stage				0.369
I/II	85(81.8)	71(34.0)	14(6.7)	
III/IV	124(18.2)	109(52.2)	15(7.2)	
Nuclear Grade				0.542
I/II	116(60.4)	97(50.5)	19(9.9)	
III/IV	76 (39.6)	66(34.4)	10(5.2)	
Renal pelvis involvement				0.04
Yes	188(90.0)	165(78.9)	23(11.0)	
No	21(10.0)	15(7.2)	6(2.9)	

--	--	--	--	--

* Significances are based on Pearson Chi-square test
Values in bold are statistically significant.
ccRCC indicates clear cell Renal Cell Carcinoma; ChRCC, chromophob Renal Cell Carcinoma and pRCC, papillary Renal Cell Carcinoma
H-score, histological score